ABSTRACr Bacteriophage X DNA can be packaged in vitro into preformed proheads to generate plaque-forming units. This complex set of reactions is initiated when X DNA is mixed with the product of the phage A gene, and proheads. Because proheads are an essential early reactant, the system has potential as an assay for the formation of biologically active proheads.
ABSTRACr Bacteriophage X DNA can be packaged in vitro into preformed proheads to generate plaque-forming units. This complex set of reactions is initiated when X DNA is mixed with the product of the phage A gene, and proheads. Because proheads are an essential early reactant, the system has potential as an assay for the formation of biologically active proheads.
When extracts of cells infected with certain X head mutants (for example, B-, C-, Nu3-, and E-) are used as the prohead donor, plaque-forming units are not produced. However, when extracts of E--and Nu3--infected cells are first reacted together the combination provides prohead-donor activity to the in vitro packaging system. In vitro assembled, biologically active proheads have the same sedimentation properties and electron microscopic appearance as "wild-typ"proheads isolated from XA D--infected cells. Centrifugation analysis shows that the Nu3-extract contributes gpE, the major capsid protein, to the reaction in the form of monomers or small polymers.
The morphogenesis of the icosahedral head of bacteriophages comprises an elaborate set of reactions in which both phage and bacterial coded factors are involved (for a review, see ref. 1) . Basically, the process can be divided into two stages: the building of the prohead and the encapsidation of the phage DNA into the preformed prohead. The latter stage has been intensively studied in the last few years and, for phages X, T7, P4, and P2, it has been possible to catalyze, in cell-free extracts, the encapsidation of exogenous DNA by isolated proheads (2) (3) (4) (5) (6) (7) (8) . Success in reproducing the earlier stage in vitro, synthesis of active proheads, has not yet been reported.
In this paper, we describe a system for phage X in which biologically active proheads are synthesized in vitro. A measure of prohead production is possible because the packaging of X DNA in vitro provides a biological assay for proheads. Proheads are an essential early reactant for the series of biochemical steps in which phage DNA, gpA, proheads, phage tails, and other phage-coded gene products interact in sequence to generate X plaque-forming units (PFU) (2) (3) (4) (5) 9) . Lambda genes B, C, Nu3, and E, and the host gene groE are the genes known to be essential in the morphogenesis of biologically active proheads (10, 11, 24) . Cells infected with phage mutants in gene E produce no heads or head-related particles since gpE is the major capsid protein (12) (13) (14) . Infection with C mutants results in the accumulation of biologically inactive prohead-like structures. Infection with phage with mutations in genes B or Nu3 similarly generates inactive proheads as well as aberrant forms such as "monsters" and tubular structures (11, 14, 15, 24) . A phenotype similar to the B-and Nu3-cases is observed in groE cell mutants infected with wild-type phage (10, 11, 16) .
Thus, when one tries to use extracts of cells infected with X mutants in genes B, C, Nu3, or E as prohead-donor, no PFU are detected (5, 11, 24) . We have explored the possibility that two extracts prepared from cells infected with two different prohead mutants can complement one another in vitro. In this communication, we report on experiments in which biologically active proheads have been synthesized by this type of complementation.
MATERIALS AND METHODS Bacterial Strains. All the bacteria used were derivatives of Escherichia coli strain K12. These were: (i) QD5003(Xi2lSam7);
(ii) 594(XAam32cI857Sam7); (iii) 594(XAam11Bamj0cI-857Sam7); (iv) 594(XAamal9Daml5cI8s7Sam7); (v) 594(XBamlocI8s7Sam7); (vi) 594(XCam42cI857Sam7); (vii) 594(XNu3amascI857Sam7); (viii) 594(XEam4cI857Sam7); (ix) W3550(Xdg805cI857Sam7); and (x) W3350.
Strains (i), (ii), (ix), and (x) have been described in ref. 5 . The prophage in strain (ix) is missing the genetic material between markers WaM812 and Wamsg9, and att. Strain (iv) was provided by N. Sternberg and is a pseudorevertant of XDam15cI857 (17) . It was provided as XAamaj9Dam15cI857; the addition of the Sam7 mutation and the introduction of this strain as prophage into 594 was done in our laboratory. Strains (iii) to (vi) and (viii) have already been described (14) , as has strain (vdi) (18) .
Source of DNA and gpA. The DNA was prepared by phenol extraction of thermally-induced cultures of strain (if) as previously stated (5) . gpA was partially purified from thermallyinduced 594(Xdg805cI87Sam7) cells as outlined in ref. 5 . The ASI fraction was used as a source of gpA in all theexperiments except for the experiment in Fig. 1A , in which the AsIl fraction was used.
Preparation of Extracts. The procedures used in preparing cell-free extracts for the assembly reaction in vitro have been described elsewhere (5) . Extracts to be used for prohead-donor activity were prepared from thermally induced cultures of strains (iv) to (viii) by ultrasonic irradiation (sonicates) as described by Becker and Gold (5) . A sonicate of induced W3350(Xdgal8scI857Sam7) sometimes served as a source of gpA. Thermally induced 594(AamllBaml0cI857Sam7) cells were always used to catalyze the second stage reaction (5), providing gpD, gpW, gpFII, and tail function to the assay (5, 24) . These second-stage extracts were prepared by the lysozyme-freeze-thaw method first described by Kaiser The sonicates are named by the lambda morphogenetic gene that bears an amber mutation. All extracts prepared after induction of the defective lysogen were incubated overnight at room temperature, then assayed for prohead activity, as described in Materials and Methods. + means that the two extracts were mixed prior to overnight incubation. * The extracts were mixed and, within one hour, a sample was tested for prohead-donor function. To assess the optimal concentration ratio of the two complementing extracts for in vitro prohead production, we *did experiments in which the concentration of one of the two extracts was kept constant while the other was varied by dilution (constant volume). Fig. 1A gives the yields of prohead activity generated in response to a 20-fold variation in the concentrations of the Nu3-and E-extracts, respectively. The data are summarized in the form of a logarithmic/logarithmic plot. The curve for the Nu3-extract (gpE donor) as variable shows a threshold and the greater slope. Operationally, the results indicate that a one-to-one ratio of the extracts is close to optimal.
Formally, the Nu3-extract should contribute gpE, gpB, gpC to the reaction. However, experiments on complementation in vitro for prohead assembly involving double-amber mutants (H. Murialdo and A. Becker, in preparation), indicate that this is not the case. In fact, Nu3-extracts contribute only gpE and gpC in active form, but no active gpB. Accordingly, an extract prepared from cells induced for the doubly-mutant prophage XC-Nu3-is a source of gpE alone, for phage-coded prohead functions. Thus, it is possible to generate a dose-response curve on gpE, without creating a variation in the concentration of the other reactants. Fig. 1B summarizes the data of an experiment where the concentration of a C-Nu3-extract was varied over two orders of magnitude in complementation with an E-extract and the yield of proheads generated measured. Again the curve is steep and shows a large threshold. Within the region of maximum slope, a doubling of gpE concentration results in a yield differential of at least three orders of magnitude. This Biochemistry: Murialdo For sedimentation analysis, Nu3-and E-extracts were mixed, incubated overnight at room temperature, and 0.1 ml of the mixture was then layered on top of a sucrose gradient, centrifuged, fractionated, and the fractions analyzed for prohead activity as described in Materials and Methods. For comparison, an A -D -extract was also incubated overnight at room temperature and subjected to identical treatment and analysis. The results are presented in Fig. 2 . It is clear that within the resolution provided by this analysis there seems to be no difference in the sedimentation velocity of the proheads made in vitro and the "wild-type" proheads obtained from A-D-extracts by the criterion of biological activity.
Molecular Nature of the gpE Involved in the Complementation Reaction In Vitro. Induction of lysogens carrying a Nu3 defective prophage results in the formation of aberrant head-related structures called "monsters" and a relatively small proportion of petit X (14, 18) . These petit X, as opposed to wild type or A-D-petit X, are not head precursors for in vitro DNA packaging reactions (11, 24, and Table 1 ). To determine whether the petit X produced upon induction of a Nu3-defective lysogen were activated to biologically active proheads by some components present in the E-extracts, we centrifuged a 1 ml sample of a Nu3-extract at 45,000 rpm for 60 min. These conditions are known to pellet petit X and monsters. A noncentrifuged sample of the Nu3 extract, as well as the supernatant of the centrifuged sample were each mixed with an E-extract, incubated overnight at room temperature, and assayed for prohead activity by standard conditions. For comparison, an A-D-extract was treated identically. The results of this experiment are presented in Table 2 .
First, these results show that ultracentrifugation indeed removed proheads very effectively from the suspension, because the prohead activity of the A -D extract dropped by a factor of more than 7 X 104 after centrifugation. The complementing activity of the Nu3-extract however remained unaltered by the same treatment. These results show that the complementing activity of the Nu3-extract is independent of the presence of the inactive petit X particles and monsters found in these extracts, and that the gpE used for complementation is in a monomeric or small oligomeric form, so that it is not removed by this type of sedimentation. * Electron Microscopic Assessment of the Elements of the Reaction and the Complementation Product. In conjunction with the above measurements of biological activity, electron microscopic observations revealed the absence of head-related particles in the E-extract. Nu3-extracts contained moderate amounts of petit X particles and monsters (Fig. Sa) which were removed by high-speed centrifugation (45,000 rpm in a 6OTi rotor for 60 min) to below the concentration at which they can be found with ease with the electron microscope under the conditions used (about I to 2 particles per grid square in a 400 mesh grid, which is approximately equivalent to about 106 particles per ml). Fig. 3b shows an electron micrograph of an A9-D-extract. There were about 2000 particles per photographic plate as an average, which is roughly equivalent to a concentration of 5 X 1010 particles per ml. The high-speed centrifugation removed these particles, again below the concentration at which they could be found in the electron microscope (picture not shown). Finally, Fig. 3c is an electron micrograph of a mixture of the E-extract and the high-speed supernatant of the Nu3 extract (compare Table 2 ), after incubation overnight at room temperature. About 130 proheads could be seen per photographic plate as an average, which is roughly equivalent to a concentration of 1.3 X 109 particles per ml. These observations show that the complementation reaction involves an extensive polymerization of relatively small components, nonobservable in the electron microscope under the reported conditions, into observable particles that resemble, at * Sedimentation velocity analyses of the complementing activity in Nu3-extracts in preparative sucrose gradients have not been successful. These failures could be due to the dilution on gradients of gpE below the concentration threshold for polymerization (Fig. 1 (19) and some small RNA-containing plant viruses (20) . For the more complex DNA-containing phages such as X, the fact that it was possible to package DNA into preformed proheads and convert the intermediate to PFU in vitro (2) (3) (4) (5) provided an opportunity to attempt to construct biologically competent proheads from prohead-precursor proteins in cell-free extracts. Indeed, as outlined in this report assembly of X proheads in vitro proceeds when two suitably complementing extracts are mixed.
The efficiency of the reaction in vitro is difficult to assess because one cannot readily estimate the concentration, for example, of active gpE added to the crude system. As a potential model for the physicochemical study of mechanism, however, it appears significant that proheads are assembled in vitro to produce a relatively large yield. Thus, by the criterion of counting prohead-like particles in the electron microscope, the ratio of such particles made in vitro to those made in vivo and extracted from an equivalent mass of XA -D --infected cells is 2-3%. Assessed by the criterion of biological activity, this ratio can be of the order of 30 percent as shown in Table 1 . It is possible that proheads made in vivo are damaged by the extraction procedure, leading to the apparent higher specific activity of the in vitro made product.
Experiments reported here show that formation of proheads proceeds when Nu3-+ E-extracts are used. Combinations of other extracts do give some complementation, but the yields are low (Table 1 ). The reasons for this latter finding are not known at present. It is possible that Nu3-and E-extracts contain preformed sub-assembly complexes that enter directly into the reaction of prohead formation, increasing its overall Biochemistry: Murialdo and Becker 910 Biochemistry: Murialdo and Becker efficiency. If so, such complexes must be absent or poorly represented in the other combinations shown in Table 1 . It is also possible that E-extracts contain an active preformed core that includes gpNu3 (18) . Conversely, Nu3-extracts may be contributing an appropriate form of gpE, the major coat subunit of proheads (11, 13) . As shown by the results described in Table  2 , active gpE derived from Nu3-extracts seems to be present in a slowly sedimenting form-a monomer, or an oligomer such as a hexamer or pentamer. It remains possible that, for some of the pairs of extracts that fail to enter a productive complementation in vitro, one or more essential gene products are present in an aberrant, irreversibly modified form-a consequence of abnormal morphogenesis in vivo due to the mutation(s) present.
The morphogenesis of X proheads proceeds through a complex set of reactions in which certain structural components of the finished prohead arise as the result of alterations of primary gene products. Thus, gpB, a polypeptide of 58,000 molecular weight, is cleaved to the form gpB* (53,000) present in finished proheads (21, 22) . The two other minor proteins, X1 and X2, are formed by the fusion of gpC to a minor fraction of gpE, and cleavage (23) . X1 and X2 differ from each other in the size of the gpC-derived moiety present (23) . gpNu3 is present only transiently during prohead assembly; is eventually lost from the nascent proheads, and seems to be extensively degraded (18) . All these protein alterations are blocked in the absence of the phage-specific gpE or gpNu3, and the host-derived gpgroE (10, 11, 18, 21, 22) . Therefore, if the product of the complementation in vitro between E-and Nu3-extracts is a biologically active prohead, as seems to be the case, these alterations are operative in vitro. The results reported here suggest that most of the events in the morphogenesis of this complex DNA-containing virus may be subject to in vitro analysis, and that the action of certain form-generating functions may be describable in biochemical terms.
We would like to thank Louis Siminovitch for continued encouragement throughout the course of this work and for his critical reading, along with Paul Sadowski, of the manuscript. We are grateful for the expert assistance of Mses. Gillian Shaw and Heather Lucko. The research was supported by the Medical Research Council of Canada (MT-3325).
